Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,413 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Cancers Clear all
Withdrawn Phase 2 Interventional

Pembrolizumab in Early Stage Colon Cancer

NCT04231526
View directory record Official record
Conditions
Colon Cancer
Interventions
Pembrolizumab, Surgery
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Chicago, Illinois • Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 4, 2026, 5:14 PM EDT
Recruiting Phase 1 Interventional

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

NCT06983743
View directory record Official record
Conditions
Metastatic Solid Tumors
Interventions
ERAS-0015, ERAS-0015 in combination
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Santa Rosa, California • Aurora, Colorado • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Completed No phase listed Observational

BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus

NCT01484925
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 4, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT05156125
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
VTX002, Placebo
Drug
Lead sponsor
Oppilan Pharma Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
19
States / cities
Garden Grove, California • Lancaster, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE

NCT04569799
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Lumason
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 4, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

NCT03257163
View directory record Official record
Conditions
Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7, Stage IIIC Gastric Cancer AJCC v7
Interventions
Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy
Drug · Other · Biological + 1 more
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Hamilton, New Jersey • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Not listed Phase 2 Interventional

A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.

NCT00152087
View directory record Official record
Conditions
Liver Cancer
Interventions
Brachytherapy
Device
Lead sponsor
St. Joseph's Hospital, Florida
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2005 · Synced Oct 4, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional

GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

NCT00110721
View directory record Official record
Conditions
Colorectal Cancer
Interventions
GM-CT-01 plus 5-Fluorouracil
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Waterbury, Connecticut • Port Saint Lucie, Florida • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

NCT00033748
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
monoclonal antibody 11D10 anti-idiotype, monoclonal antibody 3H1 Alu Gel
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
75
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 4, 2026, 5:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

NCT03693378
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
Interventions
Not listed
Lead sponsor
Immunovia, Inc.
Industry
Eligibility
Not listed
Enrollment
1,349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
13
States / cities
Stanford, California • New Haven, Connecticut • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 4, 2026, 5:14 PM EDT
Recruiting No phase listed Observational

Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions

NCT06476678
View directory record Official record
Conditions
Esophageal Neoplasm, Esophageal Polyp, Endoscopic Submucosal Dissection, Bipolar Electrocautery
Interventions
Speedboat™ Ultraslim
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

NCT06087263
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Regorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies

NCT00874263
View directory record Official record
Conditions
Colonic Polyps, Esophageal Diseases
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 4, 2026, 5:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cancer of the Pancreas Screening Study (CAPS 3)

NCT00438906
View directory record Official record
Conditions
Pancreatic Neoplasm, Peutz-Jeghers Syndrome
Interventions
Biopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma

NCT01961778
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Radio-Frequency Ablation, Cryotherapy
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 4, 2026, 5:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of a Screening Blood Test to Determine Patients' Potential Risk of Adenomatous or Advanced Colon Polyps (ACPs)

NCT01062035
View directory record Official record
Conditions
Colonic Polyp
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma

NCT02460835
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Adaptive Radiation Therapy
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 4, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT05583149
View directory record Official record
Conditions
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions
ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
Drug
Lead sponsor
Patrick C. Johnson, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Completed No phase listed Observational

Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer

NCT00897832
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm

NCT04551014
View directory record Official record
Conditions
Colo-rectal Cancer, Polyp of Colon, Adenomatous Polyp of Colon
Interventions
Use of EverLift, Without use of EverLift
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 4, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT04430738
View directory record Official record
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

NCT05673148
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Oligometastatic Colorectal Carcinoma
Interventions
Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation, Chemotherapy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
188
States / cities
Kingman, Arizona • Phoenix, Arizona • Beverly Hills, California + 146 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeted Navigation in Hepatocellular Carcinoma (HCC)

NCT06260943
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatobiliary Cancer
Interventions
Target Navigation Pilot Program
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 4, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

NCT00066651
View directory record Official record
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 4, 2026, 5:14 PM EDT